Nippon Chemiphar Turns The Tide With Increase In Generics Sales
As Company Reports Increase In Net Revenues And Decrease In Operating Loss
Japan’s Nippon Chemiphar has reported a year-on-year increase in generics sales and net revenues in the first quarter of FY21, after seeing back-to-back underwhelming quarters due to reasons such as recent National Health Insurance drug price revisions, as well as the impact of the coronavirus pandemic.
